B细胞非何杰金淋巴瘤（B-NHL）是一种来源于B细胞的淋巴恶性肿瘤，治疗困难。此外，复发和难治病例很常见。表观遗传机制异常，例如不平衡的组蛋白乙酰化影响某些基因，有助于复发和难治病例的产生。钦地美（tucidinostat）是一种新型的组蛋白去乙酰化酶抑制剂，可逆转这种表观遗传平衡，并已获批用于治疗T细胞恶性肿瘤。然而，钦地美用于B-NHL的使用仍然有限，并且缺乏相关文献加剧了这种局限性。我们进行了这一综述，以总结钦地美对B-NHL的抗癌活性及其临床应用，以克服药物耐药性。本系统综述根据PRISMA 2020指南进行，使用了MEDLINE和EBSCO的一些关键词组合。还定义了包含和排除标准。从数据库检索到的131篇文章中，有16篇被纳入综述。九篇文章显示钦地美通过改变肿瘤微环境、终止细胞周期、诱导凋亡和自噬以及增强补体依赖性和抗体依赖性细胞介导细胞毒作用来限制肿瘤进展。根据其他七项研究，将钦地美与另外一种现有的治疗方案联合使用，不仅可以使复发/难治的B-NHL患者受益，也可以使新诊断的B-NHL患者受益。钦地美在限制B-NHL进展中发挥了许多重要作用，通过表观遗传修饰。因此，将钦地美与其他抗癌药物联合使用可能对新诊断和复发/难治的B-NHL患者更有益。

B-cell non-Hodgkin lymphoma (B-NHL) is a lymphoid malignancy derived from B-cells that remains difficult to treat. Moreover, relapses and refractory cases are common. Abnormalities in epigenetic mechanisms, such as imbalanced histone acetylation affecting certain genes, contribute to relapses and refractory cases. Chidamide (tucidinostat) is a novel histone deacetylase inhibitor that can reverse this epigenetic imbalance and has been approved for the treatment of T-cell malignancies. However, the use of chidamide for B-NHL remains limited, and the lack of relevant literature exacerbates this limitation. We conducted this review to summarize the anticancer activity of chidamide against B-NHL and its clinical applications to overcome drug resistance. This systematic review was conducted according to the PRISMA 2020 guidelines, using some keyword combinations from MEDLINE and EBSCO. The inclusion and exclusion criteria were also defined. Of the 131 records retrieved from databases, 16 were included in the review. Nine articles revealed that chidamide limited tumor progression by modifying the tumor microenvironment, stopping the cell cycle, inducing apoptosis and autophagy, and enhancing complement-dependent and antibody-dependent cell-mediated cytotoxicities.According to seven other studies, administering chidamide in combination with another existing therapeutic regimen may benefit not only patients with relapsed/refractory B-NHL, but also those with newly diagnosed B-NHL. Chidamide plays many important roles in limiting B-NHL progression through epigenetic modifications. Thus, combining chidamide with other anticancer drugs may be more beneficial for patients with newly diagnosed and relapsed/refractory B-NHL.